{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:43:15Z","timestamp":1762101795107},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143338","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T18:52:36Z","timestamp":1449859956000},"page":"e0143338","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Ayanda Trevor","family":"Mnguni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan S.","family":"Borkum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bongani M.","family":"Mayosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1161\/CIRCULATIONAHA.105.542894","article-title":"Epidemiology and etiology of cardiomyopathy in Africa","volume":"112","author":"K Sliwa","year":"2005","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archinternmed.2012.3310","article-title":"The causes, treatment, and outcome of acute heart failure in 1006 Africans From 9 countries","volume":"172","author":"A Damasceno","year":"2012","journal-title":"Arch INTERN Med"},{"key":"ref3","first-page":"1","article-title":"Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis","author":"B Mayosi","year":"2014","journal-title":"N Engl J Med"},{"key":"ref4","article-title":"Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa : Causes and perioperative outcomes in the HIV era (1990\u20132012)","author":"AK Mutyaba","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/heartjnl-2012-302196","article-title":"Scientific letter: Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and Galectin-3 levels in tuberculous pericardial effusion: implications for pathogenesis and prevention of pericardial constriction","volume":"98","author":"M Ntsekhe","year":"2012","journal-title":"Heart"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.HYP.0000126172.01673.84","article-title":"Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP","volume":"43","author":"M a Cavasin","year":"2004","journal-title":"Hypertension"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1749-6632.1991.tb17230.x","article-title":"Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation","volume":"628","author":"E Bogden a","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood.V84.5.1534.1534","article-title":"The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism","volume":"84","author":"JD Cashman","year":"1994","journal-title":"Blood"},{"key":"ref9","first-page":"1","article-title":"PROSPERO International prospective register of systematic reviews The effects of Angiotensin Converting Enzyme (ACE) -inhibitors on human N- acetylseryl-aspartyl-lysyl-proline (AcSDKP) levels : a protocol for a systematic review","author":"T Mnguni","year":"2014"},{"key":"ref10","first-page":"276","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2009"},{"key":"ref11","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"D Moher","year":"2009","journal-title":"Open Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1172\/JCI118484","article-title":"Rapid Publication Acute Angiotensin-converting Enzyme Inhibition Increases the Plasma Level of the Natural Stem Cell Regulator N -Acetyl-Seryl-Aspartyl-Lysyl-Proline","volume":"97","author":"M Azizi","year":"1996","journal-title":"J Clin Investig"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.HYP.30.5.1015","article-title":"High Plasma Level of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline : A New Marker of Chronic Angiotensin-Converting Enzyme Inhibition","volume":"30","author":"M Azizi","year":"1997","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.HYP.33.3.879","article-title":"Renal and Metabolic Clearance of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in Humans","volume":"33","author":"M Azizi","year":"1999","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jpba.2010.10.009","article-title":"Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry","volume":"54","author":"K Inoue","year":"2010","journal-title":"J Pharm Biomed Anal"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1046\/j.1365-2362.1998.00356.x","article-title":"In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide","volume":"28","author":"L Comte","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(99)00439-8","article-title":"Nonadherence with Angiotensin-Converting Enzyme Inhibitor Therapy","volume":"34","author":"M Struthers","year":"1999","journal-title":"Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.HYP.35.6.1226","article-title":"In Vitro and In Vivo Inhibition of the 2 Active Sites of ACE by Omapatrilat, a Vasopeptidase Inhibitor","volume":"35","author":"M Azizi","year":"2000","journal-title":"Hypertension"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1046\/j.1440-1681.2001.03560.x","article-title":"ANGIOTENSIN I-CONVERTING ENZYME AND METABOLISM OF THE HAEMATOLOGICAL PEPTIDE N-ACETYL-SERYL-","volume":"28","author":"M Azizi","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/01.HYP.0000100423.24330.96","article-title":"Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension","volume":"42","author":"H Peng","year":"2003","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00004872-200403000-00023","article-title":"Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension","volume":"22","author":"S Rasoul","year":"2004","journal-title":"J Hypertens"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2337\/dc06-0255","article-title":"Assessment of patients\u2019 and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril","volume":"29","author":"M Azizi","year":"2006","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.106.084103","article-title":"Decreased endogenous levels of Ac-SDKP promote organ fibrosis","volume":"50","author":"M a Cavasin","year":"2007","journal-title":"Hypertension"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"H1253","DOI":"10.1152\/ajpheart.00481.2008","article-title":"Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension","volume":"295","author":"C-X Lin","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1074\/jbc.M806584200","article-title":"Angiotensin-converting enzyme is a modifier of hypertensive end organ damage","volume":"284","author":"X Liu","year":"2009","journal-title":"J Biol Chem"},{"key":"ref26","first-page":"795","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats","volume":"26","author":"M Wang","year":"2010","journal-title":"Int J Mol Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"H1114","DOI":"10.1152\/ajpheart.00300.2011","article-title":"Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats","volume":"303","author":"P Nakagawa","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.HYP.33.3.879","article-title":"Renal and Metabolic Clearance of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in Humans","volume":"33","author":"M Azizi","year":"1999","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1016\/S0021-9258(18)31543-6","article-title":"The two homologous domains of human angiotensin I-converting Enzyme are both catalytically active","volume":"266","author":"L Wei","year":"1991","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1074\/jbc.270.8.3656","article-title":"The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal Active Site of Human Angiotensin-converting Enzyme","volume":"270","author":"A Rousseau","year":"1995","journal-title":"Biol Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2353\/ajpath.2010.081127","article-title":"Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury","volume":"177","author":"P Li","year":"2010","journal-title":"Am J Pathol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/01.CIR.98.25.2788","article-title":"Inhibiting Tissue Angiotensin-Converting Enzyme","author":"LS Zisman","year":"1998","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrd1227","article-title":"Ace revisited: a new target for structure-based drug design","volume":"2","author":"KR Acharya","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/rcm.5326","article-title":"Mass spectrometric quantification of AcSDKP-NH2 in human plasma and urine and comparison with an immunoassay","volume":"26","author":"C Mesmin","year":"2012","journal-title":"Rapid Commun Mass Spectrom"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T01:19:04Z","timestamp":1653787144000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143338"}},"subtitle":[],"editor":[{"given":"Michael","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143338","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,11]]}}}